Table 3.
Overview of hypofractionated radiotherapy for prostate cancer
| Author(s) (year) [Referense no.] | Arcangeli G (2011) [11] | Fonteyne et al. (2012) [12] | Kupelian et al. (2007) [9] | Dearnaley et al. (2012) [13] | Corrent study (2014) | ||
|---|---|---|---|---|---|---|---|
| Nominal dose (Gy)/no. of fractions |
62/20 |
56/16 |
70/28 |
60/20 |
57/19 |
70/30 |
|
| Number of patients |
83 |
113 |
770 |
153 |
151 |
110 |
|
| Follow-up period (months) |
35 |
47 |
45 |
51 |
31 |
||
| CTV for T1-2 & low risk |
Prostate & seminal vesicles |
Prostate only |
Prostate only |
Prostate + base of seminal vesicles |
Prostate only |
||
| CTV for T3 & high risks |
Prostate & seminal vesicles |
Prostate & seminal vesicles |
Prostate & seminal vesicles |
Prostate & seminal vesicles |
|||
| PTV margin (mm) |
Craniocaudal |
10 |
3-10 |
5 |
5 |
5 |
3 |
| Anterior |
10 |
5 |
5 |
5 |
3 |
||
| Lateral |
10 |
8 |
5 |
5 |
3 |
||
| Posterior |
6 |
4 |
0 |
0 |
3 |
||
| Early GU (%) |
G2 |
46 |
38 |
18 |
8 |
7 |
1 |
| G3 |
1 |
0 |
1 |
0 |
0 |
0 |
|
| G4 |
0 |
0 |
0 |
0 |
0 |
||
| Early GI (%) |
G2 |
35 |
10 |
9 |
2 |
1 |
0 |
| G3 |
0 |
4 |
0 |
0 |
0 |
0 |
|
| G4 |
0 |
0 |
0 |
0 |
0 |
||
| Late GU (%) |
G2 |
8 |
10 |
5 |
2 |
0 |
3 |
| G3 |
0 |
4 |
1 |
0 |
0 |
0 |
|
| G4 |
1 |
0 |
0 |
0 |
0 |
||
| Late GI (%) |
G2 |
14 |
7 |
3 |
4 |
1 |
0 |
| G3 |
1 |
2 |
1 |
0 |
0 |
0 |
|
| G4 |
0 |
0 |
0 |
0 |
0 |
||
| Biochemical relapse free survival 5 yrs (3 yrs) % | Low |
- |
98 |
94 |
- |
- |
100 (100) |
| Intermediate |
- |
93 |
83 |
- |
- |
84 (94) |
|
| High | - | 82 | 72 | - | - | 80 (90) | |